Search the Newsreel

Nexxen International Ltd. Sponsored ADR (NASDAQ:NEXN) Receives Consensus Rating of "Moderate Buy" from Analysts

Nexxen International Ltd. (NASDAQ:NEXN) has received a "Moderate Buy" consensus rating from analysts, with nine buy ratings and one hold, and an average 12-month price target of $11.61. The stock has shown strong momentum, nearing its 52-week high, despite recent insider selling by the …

PXLW Q1 2026 Earnings: EPS of $12.46 Blows Past Estimates, Stock Advances 2.51% - Quarterly Earnings

NewtekOne, Inc. Stock 12‑Month Price Target Raised to $17.4, Implies 16% Upside

NewtekOne, Inc. (NEWT) has seen its average 12-month price target raised from $17.2 to $17.4 by five analysts, suggesting a 16% potential upside from its August 6 closing price. The consensus rating among seven covering analysts has shifted to "Buy," with two Buys, five …

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded Xencor (NASDAQ:XNCR) from "strong sell" to "hold" after the company reported better-than-expected quarterly results, including a smaller loss per share and significantly higher revenue than anticipated. Despite the upgrade and several bullish analyst price targets, the broader analyst consensus …

Lexeo Therapeutics Inc (LXEO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lexeo Therapeutics Inc (LXEO) has an earnings forecast score of 9.20, ranking 9th in its industry. Analysts have set an average price target of $18.50, with a strong buy recommendation. The company's previous EPS was -$0.27, and the next quarter's EPS is expected to …

Deluxe Q2 Earnings Call Highlights

Key Points Interested in Deluxe Corporation? Here are five stocks we like better. Deluxe delivered improved underlying performance in Q2: Comparable adjusted revenue rose 2.6%, adjusted EBITDA increased 5.3% to $108.8 million, and adjusted EPS climbed to $0.87. Payments and data businesses led growth, …

NewtekOne Inc (NEWT) Earnings Forecast: Future EPS & Revenue Growth Estimates

NewtekOne Inc (NEWT) has an earnings forecast score of 6.57, ranking 254th in the Banking Services industry, with an average price target of $14.00. Based on 7 analyst ratings, the stock currently holds a "Hold" trend. The company's expected revenue for the next quarter …

Xencor Inc (XNCR) Stock News Today

MarketAxess (NASDAQ:MKTX) Releases Earnings Results, Beats Estimates By $0.06 EPS

NewtekOne, Inc. - 8.00% Fixed Rate Senior Notes due 2028 Revenue Breakdown – NASDAQ:NEWTI

This article provides a revenue breakdown for NewtekOne, Inc.'s 8.625% Fixed Rate Senior Notes due 2029, traded under the symbol NEWTH on the Blue Ocean Alternative Trade System (BOATS). It highlights the availability of financial data, including statements, statistics, dividends, earnings, and segment performance, …

Zacks Industry Outlook WPP, Nexxen and Quad/Graphics

The Zacks Advertising and Marketing industry is facing challenges from rising costs and inflation but is adapting through increased digital marketing services and the use of artificial intelligence. WPP Plc, Nexxen International Ltd., and Quad/Graphics, Inc. are highlighted as companies navigating these challenges with …

Pixelworks Inc expected to post a loss of 20 cents a share - Earnings Preview

Pixelworks Inc. is projected to report a loss of 20 cents per share in its upcoming earnings announcement. This information comes from a Refinitiv earnings preview. The full article with more details is available through TradingView's news access.

Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses

XENON PHARMACEUTICALS INC. : WEDBUSH RAISES TARGET PRICE TO $71 FROM $63

Wedbush has increased its target price for Xenon Pharmaceuticals Inc. (XENE.O) shares to $71, up from the previous target of $63. This adjustment suggests an improved outlook from the analyst firm for the pharmaceutical company's stock. The information was released by Reuters on August …

Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss

Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business …

Xenetic partner receives Israeli approvals for lymphoma study

Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in …

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal …

Deluxe Corp (DLX) Stock News Today

This page provides current stock information for Deluxe Corp (DLX), including its market cap, P/E ratio, and recent stock performance. It states that more news is coming soon for the company and encourages users to stay tuned for updates on earnings, analyst ratings, and …

MarketAxess Holdings Inc. (NASDAQ: MKTX) posts $68,323 Q2 profit

MarketAxess Holdings 2Q 2026: Revenue $218.4M, EPS $1.93— 10-Q Summary

MarketAxess Holdings reported its second-quarter 2026 results, showing revenue of $218.4 million and diluted earnings per share of $1.93. While net income and total revenue saw slight year-over-year decreases, year-to-date revenues increased by 5.6% driven by commission growth and strong information services. The company …

Fidelity Climate Action Fund's MarketAxess Holdings Inc(MKTX) Holding History

This article details the Fidelity Climate Action Fund's investment in MarketAxess Holdings Inc (MKTX). As of May 31, 2026, the fund held 3,584 shares valued at $466,060, constituting 0.82% of its portfolio. The initial purchase occurred in Q2 2026 at an average price of …

Lanxess AG (LNXSF) (Q2 2026) Earnings Call Highlights: Operational Turning Point Drives ...

This article first appeared on GuruFocus. EBITDA: Strong sequential increase in Q2 2026, in line with company expectations. Cash Flow: Improved in Q2 2026, driven by tight net working capital management, especially on the inventory side. Net Financial Debt: Consistently reduced over the last …

Nexxen International Ltd (NEXN) Stock News Today

This article provides the latest stock news for Nexxen International Ltd (NEXN) on TradingKey. It displays current stock performance, market capitalization, and P/E ratio. The content indicates that more news will be coming soon for the company.

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

Xenon Pharmaceuticals' (XENE) recent pre-NDA meeting with the FDA for azetukalner appeared construct PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? …

Crexendo Inc (CXDO) Stock News Today

This article provides the latest news and financial data for Crexendo Inc (CXDO), a software and IT services company. It highlights the company's recent Q2 2026 earnings, where service revenue drove a 49% growth. The current stock price, market capitalization, and P/E ratio are …

Exelixis, Inc. Stock 12‑Month Price Target Raised to $52.62, Implies 7% Downside

Exelixis, Inc.'s average stock price target has been raised from $52.25 to $52.62 by 16 analysts, suggesting a potential 7% downside based on the August 5 closing price. Despite the raised target implying a decrease, the consensus rating for EXEL remains a "Buy" from …

EXELIXIS INC EXELIXIS ORD SHS (0IJO.L) Q4 FY2025 earnings call transcript

Exelixis reported Q4 2025 revenues of $599M, primarily driven by a 6% year-over-year increase in U.S. CABOMETYX sales to $547M, with full-year 2025 U.S. CABOMETYX revenue reaching $2.12B, up 17% year-over-year. The company is preparing for a potential late 2026 launch of zanzalintinib for …

Quantinno Capital Management LP Boosts Holdings in Exelixis, Inc. $EXEL

Quantinno Capital Management LP significantly increased its stake in Exelixis, Inc. by 44.3% in the first quarter, now holding 115,592 shares valued at approximately $4.96 million. This increase occurred despite mixed analyst ratings and recent insider selling. Exelixis reported strong second-quarter adjusted earnings but …

Exelon Corporation $EXC Holdings Decreased by Bank of America Corp DE

Bank of America Corp DE reduced its stake in Exelon Corporation by 19.8% in the first quarter, selling 1.57 million shares and retaining 6.34 million shares valued at $310.6 million. Despite this, Exelon reported a 10% year-over-year revenue increase to $5.97 billion in Q2 …

Xenetic Biosciences reports Q2 results

* Xenetic Biosciences press release [https://seekingalpha.com/pr/20611787-xenetic-biosciences-reports-second-quarter-2026-financial-results-and-highlights-strengthened] (XBIO [https://seekingalpha.com/symbol/XBIO]): Q2 * Royalty revenue for the three months ended June 30, 2026, increased approximately 12% to $0.7 million, compared to approximately $0.6 million for the comparable prior-year period. * Net loss for the quarter ended June …

Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary

Xeris Biopharma Holdings, Inc. reported its 2026 quarterly results with revenue reaching $92.1 million, an increase of 28.7% year-over-year. Despite the revenue growth, the company recorded a net loss of ($31.1M) and a diluted EPS of ($0.18), driven by higher product sales and increased …

Xerox Holdings Co. Plans Quarterly Dividend of $0.03 (NASDAQ:XRX)

Xerox Holdings Co. (NASDAQ:XRX) has declared a quarterly dividend of $0.025 per share, payable on October 30th to shareholders of record on September 30th. This translates to an annualized dividend yield of 3.2%. Despite a slight annual decrease in dividend payments over the last …

NewtekOne, Inc. - 8.625% Fixed Rate Senior Notes due 2029 Revenue Breakdown – BOATS:NEWTH

This article provides a revenue breakdown for NewtekOne, Inc.'s 8.625% Fixed Rate Senior Notes due 2029, traded under the symbol NEWTH on the Blue Ocean Alternative Trade System (BOATS). It highlights the availability of financial data, including statements, statistics, dividends, earnings, and segment performance, …

Xenetic Biosciences: Q2 Earnings Snapshot

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

Xencor, Inc. (NASDAQ:XNCR) has received a consensus "Hold" recommendation from brokerages, with nine firms providing ratings. The biopharmaceutical company recently reported a quarterly loss of $0.29 per share, exceeding analyst estimates, and saw its revenue increase by 17.4% year over year. Several institutional investors …

Xenora Minerals (ASX:XRA) Shares Rise 11% as Dudley Lithium Work Continues